Profile

Brandon K. Hadland, MD, PhD

Brandon K. Hadland, MD, PhD

Hematology-Oncology

On staff since July 2012

"I am amazed and humbled every day by the strength and resilience of our patients and their families; they are an inspiration for us to continue the pursuit of researching novel therapies and improving clinical care. My long-term research goal is to generate new sources of blood stem cells that could one day be used to correct inherited, blood-based diseases."

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

Washington University School of Medicine, St Louis

Residency

Pediatrics, University of Washington/Seattle Children's Hospital, Seattle

Fellowship

Hematology, University of Washington, Seattle
Hematology, University of Washington, Seattle

Clinical Interests

Stem cell transplant

Research Description

Signal pathways regulating hematopoietic stem cell development

Awards and Honors

Award Name Award Description Awarded By Award Date
Alpha Omega Alpha Honor Medical Society 2006
Chemistry Departmental Honors Phi Lambda Upsilon Honorary Chemical Society 1998

Publications

  • Doulatov S, Vo LT, Chou SS, Kim PG, Arora N, Li H, Hadland BK, Bernstein ID, Collins JJ, Zon LI, Daley GQ
    Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors.
    Cell stem cell , 2013 Oct. : 13(4)459-70
  • Palpant NJ, Pabon L, Rabinowitz JS, Hadland BK, Stoick-Cooper CL, Paige SL, Bernstein ID, Moon RT, Murry CE
    Transmembrane protein 88: a Wnt regulatory protein that specifies cardiomyocyte development.
    Development (Cambridge, England) , 2013 Sept. : 140(18)3799-808
  • Hadland BK, Bernstein ID
    Visualizing human ESC-derived hematopoiesis.
    Blood , 2013 Jan. : 121(5)717-8
  • Hadland BK, Longmore GD
    Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Sept. : 27(25)4217-26
  • Vooijs M, Ong CT, Hadland B, Huppert S, Liu Z, Korving J, van den Born M, Stappenbeck T, Wu Y, Clevers H, Kopan R
    Mapping the consequence of Notch1 proteolysis in vivo with NIP-CRE.
    Development (Cambridge, England) , 2007 Feb. : 134(3)535-44
  • Hadland BK, Huppert SS, Kanungo J, Xue Y, Jiang R, Gridley T, Conlon RA, Cheng AM, Kopan R, Longmore GD
    A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development.
    Blood , 2004 Nov. : 104(10)3097-105
  • Nichols AM, Pan Y, Herreman A, Hadland BK, De Strooper B, Kopan R, Huppert SS
    Notch pathway is dispensable for adipocyte specification.
    Genesis (New York, N.Y. : 2000) , 2004 Sept. : 40(1)40-4
  • Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS, Schroeter EH, Kopan R
    Gamma -secretase inhibitors repress thymocyte development.
    Proceedings of the National Academy of Sciences of the United States of America , 2001 June : 98(13)7487-91
  • Brandon K. Hadland, MD, PhD
    A molecular phylogenetic analysis of reproductive trait evolution in the soft coral genus Alcyonium
    Evolution Int J Org Evolution , 2001 : 5554-67

Research Funding

Grant Title Grantor Amount Award Date
T32 CA009351 NCI: Pediatric Oncology Training Program NCI
K12 CA076930 Career Development in Pediatric and Medical Oncology NIH $